ATXS Insider Trading Activity and SEC Form 4 Filings
ATXS insider trading summary
No open-market insider purchases or sales of Astria Therapeutics, Inc. (ATXS) have been reported on SEC Form 4 in the past 12 months.
Latest ATXS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Apr 1, 2024 | Christopher Morabito | Chief Medical Officer | Sell | $136K (10,000 @ $13.59) |
| Feb 1, 2024 | Joseph Edelman | Director | Buy | $30.0M (2,481,350 @ $12.09) |
| Feb 1, 2024 | Perceptive Advisors LLC | Director | Buy | $30.0M (2,481,350 @ $12.09) |
| Feb 1, 2024 | Perceptive Xontogeny Venture Fund, LP | Director | Buy | $30.0M (2,481,350 @ $12.09) |
| Feb 1, 2024 | Perceptive Life Sciences Master Fund Ltd | Director | Buy | $30.0M (2,481,350 @ $12.09) |
| Jan 29, 2024 | Christopher Morabito | Chief Medical Officer | Sell | $103K (9,200 @ $11.15) |
| Jan 26, 2024 | Christopher Morabito | Chief Medical Officer | Sell | $9K (800 @ $11.02) |
| Dec 21, 2023 | Perceptive Life Sciences Master Fund Ltd | Director | Buy | $4.6M (740,000 @ $6.20) |
| Dec 21, 2023 | Perceptive Xontogeny Venture Fund, LP | Director | Buy | $4.6M (740,000 @ $6.20) |
| Dec 21, 2023 | Perceptive Advisors LLC | Director | Buy | $4.6M (740,000 @ $6.20) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.